BNTX

BioNTech SE

89.82 USD

Last updated Oct 14, 16:02 UTC

Yesterday HIGH

$93.08

Yesterday LOW

$88.86

52w HIGH

$123.98

52w LOW

$79.52

EPS

-2.58

PE

-34.81

Next Earnings

Nov 3, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

BioNTech SE stock is down -9.14% since 30 days ago. The next earnings date is Nov 3, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 7 October’s closed higher than September. In the last 10 Unusual Options Trades, there were 6 CALLs, 4 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

07 Oct 13:37	21 May, 2027	70.00	CALL	100	100
08 Oct 15:45	21 May, 2027	70.00	CALL	100	200
08 Oct 17:55	18 Dec, 2026	97.50	CALL	70	54
09 Oct 13:36	20 Nov, 2026	100.00	CALL	198	131
09 Oct 13:52	21 May, 2027	70.00	CALL	100	400
12 Oct 14:00	18 Dec, 2026	85.00	PUT	170	570
13 Oct 14:31	21 Jan, 2028	80.00	PUT	33	22
13 Oct 15:25	19 Mar, 2027	100.00	PUT	60	10
13 Oct 18:40	19 Mar, 2027	70.00	PUT	115	80
14 Oct 15:20	18 Dec, 2026	95.00	CALL	100	340

Advanced Data Unlock

Evette Mitkov

Fri Aug 28, 2026

BioNTech Stock Dips After BNT122-01 Trial Termination

BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene cevumeran in resected colorectal cancer.
Benzinga Newsdesk

Fri Aug 28, 2026

BioNTech shaes are trading lower after the company announced it will terminate its Phase 2 BNT122-01 trial.
Benzinga Newsdesk

Fri Aug 28, 2026

BioNTech Says It Will Terminate Phase 2 BNT122-01 Trial Of Autogene Cevumeran In ctDNA-Positive Resected Colorectal Cancer After DSMB Identified Numerical Overall Survival Imbalance Between Arms; No New Safety Signals

https://www.sec.gov/Archives/edgar/data/1776985/000177698526000061/a991260828_bntxxcrcxenxfin.htm
Benzinga News-desk

Thu Aug 27, 2026

QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax

FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.
Benzinga Newsdesk

Thu Aug 27, 2026

FDA Approves Pfizer And BioNTech's Supplemental Biologics License Application For 2026-2027 COVID-19 Vaccine Formula

2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variantsShipping will begin immediately to ensure rapid access to this season’s
Vandana Singh

Fri Aug 21, 2026

Why Is Arbutus Biopharma Stock Gaining Friday?

Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.
Benzinga News-desk

Fri Aug 21, 2026

BioNTech shares are trading higher. Yesterday, the company announced it will present clinical data from its diversified development program in lung cancer treatment at the IASLC 2026 World Conference on Lung Cancer.
Surbhi Jain

Thu Aug 20, 2026

Merck and Moderna's Phase 3 Win Raises the Stakes for BioNTech and Roche (CORRECTED)

Merck & Moderna's partnership reports first Phase 3 success for personalized cancer vaccine, raising stakes for BioNTech & Genentech's program.
Benzinga Newsdesk

Thu Aug 20, 2026

BioNTech Will Present New Data From Its Development Program in Lung Cancer Treatment at the IASLC 2026 World Conference on Lung Cancer In September; Data Highlights Progress Across Pumitamig (BNT327/BMS986545) and Gotistobart (BNT316/ONC-392), As Well As BioNTech’s mRNA-Based Immunotherapy Approaches

Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNTech’s leadership in
Mohd Haider

Thu Aug 20, 2026

Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight

Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results.

Morgan Stanley

Wed Oct 7, 16:23

buy

confirm

Advanced Data Unlock

Ugur Sahin, Chief Executive Officer

Thu Oct 8, 2026

BNTX Recent Insider Trades and Stock Chart

27,000 shares sold
Ugur Sahin, Chief Executive Officer

Fri Oct 9, 2026

BNTX Recent Insider Trades and Stock Chart

36,209 shares sold
Ugur Sahin, Chief Executive Officer

Wed Oct 7, 2026

BNTX Recent Insider Trades and Stock Chart

24,000 shares sold
Ugur Sahin, Chief Executive Officer

Tue Oct 6, 2026

BNTX Recent Insider Trades and Stock Chart

21,000 shares sold
Ugur Sahin, Chief Executive Officer

Mon Oct 5, 2026

BNTX Recent Insider Trades and Stock Chart

72,000 shares sold
Ugur Sahin, Chief Executive Officer

Thu Oct 1, 2026

BNTX Recent Insider Trades and Stock Chart

17,000 shares sold
Ugur Sahin, Chief Executive Officer

Fri Oct 2, 2026

BNTX Recent Insider Trades and Stock Chart

17,000 shares sold
Ugur Sahin, Chief Executive Officer

Tue Sep 29, 2026

BNTX Recent Insider Trades and Stock Chart

34,000 shares sold
Ugur Sahin, Chief Executive Officer

Wed Sep 30, 2026

BNTX Recent Insider Trades and Stock Chart

32,000 shares sold
Ugur Sahin, Chief Executive Officer

Mon Sep 28, 2026

BNTX Recent Insider Trades and Stock Chart

34,000 shares sold
Ugur Sahin, Chief Executive Officer

Fri Sep 25, 2026

BNTX Recent Insider Trades and Stock Chart

27,000 shares sold
Ugur Sahin, Chief Executive Officer

Wed Sep 23, 2026

BNTX Recent Insider Trades and Stock Chart

30,000 shares sold
Ugur Sahin, Chief Executive Officer

Thu Sep 24, 2026

BNTX Recent Insider Trades and Stock Chart

39,000 shares sold
Ugur Sahin, Chief Executive Officer

Tue Sep 22, 2026

BNTX Recent Insider Trades and Stock Chart

46,000 shares sold
Ugur Sahin, Chief Executive Officer

Mon Sep 21, 2026

BNTX Recent Insider Trades and Stock Chart

33,000 shares sold
Ugur Sahin, Chief Executive Officer

Thu Sep 17, 2026

BNTX Recent Insider Trades and Stock Chart

34,000 shares sold
Ugur Sahin, Chief Executive Officer

Fri Sep 18, 2026

BNTX Recent Insider Trades and Stock Chart

30,000 shares sold
Ugur Sahin, Chief Executive Officer

Wed Sep 16, 2026

BNTX Recent Insider Trades and Stock Chart

15,000 shares sold
Ugur Sahin, Chief Executive Officer

Tue Sep 15, 2026

BNTX Recent Insider Trades and Stock Chart

34,000 shares sold
Ugur Sahin, Chief Executive Officer

Mon Sep 14, 2026

BNTX Recent Insider Trades and Stock Chart

41,000 shares sold
Ugur Sahin, Chief Executive Officer

Fri Sep 11, 2026

BNTX Recent Insider Trades and Stock Chart

45,000 shares sold